Danaher Corporation $DHR Shares Acquired by MPS Loria Financial Planners LLC

MPS Loria Financial Planners LLC grew its holdings in Danaher Corporation (NYSE:DHR) by 46.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 7,656 shares of the conglomerate’s stock after buying an additional 2,413 shares during the quarter. Danaher makes up about 0.3% of MPS Loria Financial Planners LLC’s investment portfolio, making the stock its 24th largest holding. MPS Loria Financial Planners LLC’s holdings in Danaher were worth $1,696,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Marquette Asset Management LLC increased its stake in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after buying an additional 73 shares during the period. N.E.W. Advisory Services LLC bought a new position in shares of Danaher during the second quarter valued at approximately $25,000. Main Street Group LTD bought a new position in shares of Danaher during the first quarter valued at approximately $25,000. Field & Main Bank purchased a new stake in Danaher in the second quarter worth $29,000. Finally, Evolution Wealth Management Inc. lifted its stake in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock worth $29,000 after acquiring an additional 104 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. The Goldman Sachs Group upped their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Morgan Stanley upped their price objective on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a report on Monday. Barclays raised their target price on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, Evercore reaffirmed an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Trading Up 0.8%

DHR opened at $224.65 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The stock has a market cap of $157.93 billion, a PE ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The business has a 50 day moving average of $212.92 and a 200-day moving average of $195.39.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.77 earnings per share. Equities research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.